Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure

Journal of the American College of Cardiology

Volumn 31, Issue 6, 1998, Pages 1336-1340

  Shakar, Simon F ^a   Abraham, William T ^a   Gilbert, Edward M ^b   Robertson, Alastair D ^a   Lowes, Brian D ^a   Zisman, Lawrence S ^a   Ferguson, Debra A ^a   Bristow, Michael R ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ENOXIMONE; INOTROPIC AGENT; METOPROLOL; PHOSPHODIESTERASE INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG MIXTURE; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEART FAILURE; HOSPITAL ADMISSION; HUMAN; MALE; PRIORITY JOURNAL;

EID: 0032080759     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00077-1     Document Type: Article

References (34)

1. 1. Pfeffer MA, Braunwald R, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival And Ventricular Enlargement trial. N Engl J Med 1992;327:669-77.
2. 2. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian ENalapril SUrvival Study (CONSENSUS). N Engl J Med 1987;316: 1429-35.
3. 3. Bristow MR, Gilbert EM, Abraham WT, et al., for the MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996;94:2807-16.
4. 4. Packer M, Bristow MR, Cohn JN, et al., for the U.S. Carvedilol Heart Failure Study Group. The effect of Carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
5. 5. Eichhorn EJ, Hersh CM, Barnett JH, et al. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 1994;24:1310-20.
6. 6. Colucci WS, Packer H, Bristow MR, et al., for the U.S. Carvedilol Heart Failure Study Group. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996;94:2800-6.
7. 7. Waagstein F, Bristow MR, Swedberg K, et al., for the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1441-6.
8. 8. Bristow MR, O'Connell JB, Gilbert EM, et al., for the Bucindolol Investigators. Dose response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation 1994;89:1632-42.
9. 9. Krum H, Sackner-Bernstein JD, Goldsmith R, et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 1995;92:1499-1506.
10. 10. Australia-New Zealand Heart Failure Research Collaborative Group. Effect of carvedilol, a vasodilator-β-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation 1995;92:212-18.
11. 11. Packer M, Carver JR, Rodeheffer RJ, et al., for the PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991;325:1468-75.
12. 12. Cowley AJ, Skene AM, on behalf of the Enoximone Investigators. Treatment of severe heart failure: quantity or quality of life? A trial of enoximone. Br Heart J 1994;72:226-30.
13. 13. Krell MJ, Kline EM, Bates ER, et al. Intermittent, ambulatory dobutamine infusion in patients with severe congestive heart failure. Am Heart J 1986;112:787-91.
14. 14. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992;20:248-54.
15. 15. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L, for the CONSENSUS Trial Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990;82:1730-6.
16. 16. Cohn J, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-23.
17. 17. Vernon MW, Heel RC, Brogden RN. Enoximone: a review of its pharmacological properties and therapeutic potential. Drugs 1991;42:997-1017.
18. 18. The Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet 1990;336:1-6 [Erratum, Lancet 1990;336:968].
19. 19. Uretsky BF, Jessup M, Konstam M, et al., for the Enoximone Multicenter Trial Group. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure: lack of benefit compared to placebo. Circulation 1990;82:774-80.
20. 20. Dyer AR, Persky V, Stamler J, et al. Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiological studies. Am J Epidemiol 1980;112:736-49.
21. 21. Shivalkar B, VanLoon J, Wieland W, et al. Variable effects of explosive or gradual increase of intracranial pressure on myocardial structure and function. Circulation 1993;87:230-9.
22. 22. Rosenbaum JS, Ginsburg R, Billingham MR, Huffman BB. Effects of adrenergic receptor antagonists on cardiac morphological and functional alterations in rats harboring pheochromocytoma. J Pharmacol Exp Ther 1987;241:354-60.
23. 23. Mann DL, Kent RL, Parsons B, Cooper IVG. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 1992;85:790-804.
24. 24. Packer M, Colucci WS, Sackner-Bernstein JD, et al., for the PRECISE Study Group. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: the PRECISE trial. Circulation 1996;94:2793-9.
25. 25. Kendall MJ, Lynch KP, Hjalmarson A, Kjekshus J. Beta-blockers and sudden cardiac death. Ann Intern Med 1995;123:358-67.
26. 26. Bristow MR. Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents. Am J Cardiol 1993;71:12C-22C.
27. 27. Bristow MR. Changes in myocardial and vascular receptors in heart failure [abstract]. J Am Coll Cardiol 1993;22 Suppl A:61A-71A.
28. 28. Gilbert EM, Bristow MR, Mason JW. The acute hemodynamic response to low-dose enoximone (MDL 17,043): an oral dose-range study. Am J Cardiol 1987;82:202-6.
29. 29. Narahara A, and the Western Enoximone Study Group. Oral enoximone therapy in chronic heart failure: a placebo-controlled randomized trial. Am Heart J 1991;121:1471-9.
30. 30. Jondeau G, Dubourg O, Delorme G, et al. Oral enoximone as a substitute for intravenous catecholamine support in end-stage congestive heart failure. Eur Heart J 1994;15:242-6.
31. 31. Lee RL, Hershberger RE, Port JD, et al. Low-dose enoximone in subjects awaiting cardiac transplantation. J Thorac Cardiovas Surg 1991;102:246-58.
32. 32. Galie N, Branzi A, Magnani G, et al. Effect of enoximone alone and in combination with metoprolol on myocardial function and energetics in severe congestive heart failure: improvement in hemodynamic and metabolic profile. Cardiovasc Drugs Ther 1993;7:337-47.
33. 33. Travill CM, Pugh S, Noble MI. The inotropic and hemodynamic effects of intravenous milrinone when reflex adrenergic stimulation is suppressed by beta-adrenergic blockade. Clin Ther 1994;16:783-92.
34. 34. Hoeper MM, Boeker KHW. Overdose of metoprolol treated with enoximone [letter]. N Engl J Med 1996;335:1538.